Search Results
Feb 24, 2026, 09:01 ET Mrs. T's® Pierogies Launches "Pass the Pierogy" to Help Parents Build Supportive Villages
carrierExclusive coupons for free boxes of Mrs. T's PierogiesA recipe card packed with meal inspirationMrs. T's branded oven mitt and spatulaWith Pass the Pierogy bundles, showing up for your people doesn't have to mean adding more to your plate — it can simply mean
More news about: Mrs. T's Pierogies
Feb 19, 2026, 08:00 ET Sprinter Health Increases Healthcare Access Through Expansion of Preventive Care+ Visits Across 25 States
Mitt Coats, M.D. and
More news about: Sprinter Health
Feb 18, 2026, 06:45 ET Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight
(2018-2024). Presented at Maui Derm, 2026.2 Hypothetical estimand in the modified intent-to-treat (mITT) population is used. The hypothetical estimand represents efficacy in all mITT participants who remained on study intervention without initiating prohibited medication.3 Enos,
More news about: Eli Lilly and Company
Feb 12, 2026, 07:30 ET Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
patient populations, for which, the primary endpoint of progression free survival will be tested sequentially: 1) a modified intent to treat population (mITT) that will include patients with either, a) TP53 wild-type tumors with proficient mismatch repair status (pMMR); or, b) TP53 wild-type
More news about: Karyopharm Therapeutics Inc.
Jan 22, 2026, 12:30 ET Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)
frequency (coughs per hour), as determined by an objective cough monitor, for the modified intent-to-treat (mITT) population at the end of Week 6 versus Baseline for nalbuphine ER compared to placebo. The mITT population consisted of all patients who were randomized and received at least one dose of study drug
More news about: Trevi Therapeutics, Inc.
Jan 12, 2026, 07:00 ET Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
survival will be tested sequentially and the key secondary endpoint of overall survival will be evaluated: 1) a modified intent to treat population (mITT) that will include patients with either, a) TP53 wild-type tumors with proficient mismatch repair status (pMMR); or, b) TP53 wild-type
More news about: Karyopharm Therapeutics Inc.
Jan 08, 2026, 14:00 ET Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight
Hypothetical efficacy estimand in the modified intent-to-treat (mITT) population is used. The hypothetical efficacy estimand represents efficacy in all mITT participants who remained on study intervention without initiating prohibited medication.
More news about: Eli Lilly and Company
Dec 16, 2025, 07:30 ET REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata
timepoints, the rezpegaldesleukin treatment arms separated from placebo in the study.Four of 92 patients included in the modified intent-to-treat (mITT) analysis were found to have major study eligibility violations that should have disqualified them for randomization into the trial.Both rezpegaldesleukin
More news about: Nektar Therapeutics
Dec 12, 2025, 21:48 ET Loop lanserar en flugfiskeserie på YouTube som belyser bevarande och anknytning
vårt miljöuppdrag på Cox. Och för mig är det personligt", säger Alex Taylor, ordförande och vd på Cox Enterprises. "Jag har tillbringat större delen av mitt liv med att fiska lax, och om jag kan göra något innan jag dör, kommer jag att vara mycket glad om det skyddar en flod för alltid.""Hos Loop
More news about: Loop
Nov 26, 2025, 14:15 ET InventHelp Inventor Develops Device to Remove Placenta Particles (CSK-797)
particles from the uterus when the placenta was retained during a vaginal delivery," said an inventor, from Mt Pleasant, S.C., "so I invented the HAND MITT SPONGE. My design offers an improved alternative to using a sterile glove or being rushed to an operating room."
More news about: InventHelp
Nov 18, 2025, 08:00 ET Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals
program. The primary efficacy analysis will be performed using a Modified Intent-To-Treat (mITT) population. This will result in an estimated 450 subjects in the mITT population, randomized in a 1:1 ratio to either ibezapolstat or standard- of-care vancomycin, enrolled into the
More news about: Acurx Pharmaceuticals, Inc.
Nov 17, 2025, 15:00 ET BRUCE BOLT AND FERNANDO TATIS JR. DROP MLB-STAR'S FIRST SIGNATURE SERIES BATTING GLOVE AND PROTECTIVE GEAR
elastic wrap adds support and power Protective Gear, Leg Guard ($90) Protective Gear, Sliding Mitt ($70) Protective Gear, Elbow Guard ($70)
More news about: BRUCE BOLT, LLC
Nov 10, 2025, 08:00 ET Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens
program. The primary efficacy analysis will be performed using a Modified Intent-To-Treat (mITT) population. This will result in an estimated 450 subjects in the mITT population, randomized in a 1:1 ratio to either ibezapolstat or standard- of-care vancomycin, enrolled into the
More news about: Acurx Pharmaceuticals, Inc.
Nov 05, 2025, 07:30 ET DeepL presenterar nästa generations AI-verktyg för språk och en banbrytande produktivitetslösning
genom att minimera manuella granskningar. Tillsammans omdefinierar de effektivitet, hastighet och skala, vilket gör det möjligt för företag att blomstra mitt i de ständigt föränderliga kraven på språk och arbete." "Genom att kombinera intelligenta verktyg med mänsklig expertis förbättrar
More news about: DeepL
Nov 03, 2025, 07:00 ET Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress
survival will be tested sequentially and the key secondary endpoint of overall survival will be evaluated: 1) a modified intent to treat population (mITT) that will include patients with either, a) TP53 wild-type tumors with proficient mismatch repair status (pMMR); or, b) TP53 wild-type tumors with deficient
More news about: Karyopharm Therapeutics Inc.
Oct 28, 2025, 08:00 ET Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference
program. The primary efficacy analysis will be performed using a Modified Intent-To-Treat (mITT) population. This will result in an estimated 450 subjects in the mITT population, randomized in a 1:1 ratio to either ibezapolstat or standard- of-care vancomycin, enrolled into the
More news about: Acurx Pharmaceuticals, Inc.
Oct 17, 2025, 08:00 ET Apnimed To Present Additional Phase 3 Data for AD109, an Investigational Oral Pill for Obstructive Sleep Apnea, at CHEST 2025 Annual Meeting
with OSA can find a solution that works for them." Select SynAIRgy Phase 3 Results In the mITT population, AD109 achieved a significant reduction in mean AHI from baseline (55.6%, p<0.0001) compared to placebo (19.1%, p<0.0001) at 26 weeks.
More news about: Apnimed, Inc.
Oct 14, 2025, 07:10 ET Final analysis of open-label extension (OLE) study of FINTEPLA® (fenfluramine) in Lennox-Gastaut syndrome published in Epilepsy & Behavior
change in the frequency of seizures associated with a fall from Month 2 to the end of the study (−31.1%, P<0.0001, n=240, modified intent-to-treat (mITT) population), with reductions of −27.6% in pediatric patients (n=170, P=0.0005) and −40.0% in adults (n=70, P<0.0001). At
More news about: UCB
Oct 08, 2025, 07:30 ET Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting
frequency (coughs per hour), as determined by an objective cough monitor, for the modified intent-to-treat (mITT) population at the end of Week 6 versus Baseline for nalbuphine ER compared to placebo. The mITT population consisted of all patients who were randomized and received at least one dose of study drug
More news about: Trevi Therapeutics, Inc.
Oct 08, 2025, 07:00 ET Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis
survival will be tested sequentially and the key secondary endpoint of overall survival will be evaluated: 1) a modified intent to treat population (mITT) that will include patients with either, a) TP53 wild-type tumors with proficient mismatch repair status (pMMR); or, b) TP53 wild-type tumors with deficient
More news about: Karyopharm Therapeutics Inc.
Sep 30, 2025, 07:30 ET Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection
program. The primary efficacy analysis will be performed using a Modified Intent-To-Treat (mITT) population. This will result in an estimated 450 subjects in the mITT population, randomized in a 1:1 ratio to either ibezapolstat or standard- of-care vancomycin, enrolled into the
More news about: Acurx Pharmaceuticals, Inc.